Aries Wealth Management Verastem, Inc. Transaction History

Aries Wealth Management

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 11, 2023	BUY	$0.39 - $0.71 $17,550 - $31,950	45,000 Added 86.54%	97,000 $40,000
Q4 2022 Jan 18, 2023	BUY	$0.33 - $10.44 $9,240 - $292,320	28,000 Added 116.67%	52,000 $0
Q2 2022 Jul 27, 2022	BUY	$1.02 - $1.83 $24,480 - $43,920	24,000 New	24,000 $28,000
Q1 2022 Apr 25, 2022	SELL	$1.06 - $2.1 $23,320 - $46,200	-22,000 Closed	0 $0
Q4 2021 Jun 06, 2022	SELL	$2.05 - $3.2 $270,600 - $422,400	-132,000 Reduced 85.71%	22,000 $45,000
Q4 2021 Jan 18, 2022	BUY	$2.05 - $3.2 $270,600 - $422,400	132,000 Added 600.0%	154,000 $316,000
Q3 2021 Oct 13, 2021	BUY	$2.54 - $4.07 $5,080 - $8,140	2,000 Added 10.0%	22,000 $68,000
Q4 2020 Jan 22, 2021	BUY	$1.15 - $2.4 $11,500 - $24,000	10,000 Added 100.0%	20,000 $51,000
Q2 2020 Jul 09, 2020	BUY	$1.69 - $4.2 $16,900 - $42,000	10,000 New	10,000 $17,000
Q1 2020 Apr 09, 2020	SELL	$1.26 - $3.38 $25,203 - $67,610	-20,003 Closed	0 $0
Q4 2019 Jan 13, 2020	BUY	$0.86 - $1.44 $8,600 - $14,400	10,000 Added 99.97%	20,003 $26,000
Q3 2019 Oct 22, 2019	BUY	$1.21 - $1.59 $12,103 - $15,904	10,003 New	10,003 $11,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $779M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Aries Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Aries Wealth Management with notifications on news.